Jan Witowski and Krzysztof Geras

One of the challenges of treating cancers is that they aren’t created equal. Some are fast and aggressive, others slow with lower risk. It’s often difficult to tell which is which, challenging to guide the course of treatment and leading to therapies whose risks outweigh the dangers of the cancer. There are some lab tests that can help, but it can take days or weeks to get results and their usefulness is sometimes specific to patients with specific genetic mutations.

Jan Witowski wants to change this. His company, Ataraxis, has developed an AI-power diagnostic test, Ataraxis Breast, that can accurately assess whether a breast cancer is high risk or low risk , giving doctors insight as to whether a patient needs aggressive treatment. In a recent study, the company said that its system could be up to 30% more accurate than the current standard of care used in many hospitals today.

“If you don’t benefit from chemotherapy, you want to avoid it,” CEO Witowski said.........

© Forbes